CAR-T细胞疗法在自身免疫性疾病中的应用
尽管自身免疫性疾病临床管理取得巨大进展,许多患者对现有治疗无应答。自体CD19 CAR-T细胞已用于治疗自身免疫病,可快速持续清除循环B细胞,并使难治性系统性红斑狼疮和皮肌炎获得完全临床和血清学缓解。本文讨论通过CAR-T细胞靶向自身反应性B细胞的演进策略。
要点
- 自体CD19 CAR-T细胞可快速持续清除循环B细胞。
- 难治性系统性红斑狼疮和皮肌炎可获得完全临床和血清学缓解。
- 靶向自身反应性B细胞的CAR-T策略仍在演进中。
核心结论
- 自体CD19 CAR-T细胞可快速持续清除循环B细胞,并使难治性系统性红斑狼疮和皮肌炎获得完全临床和血清学缓解。
- 靶向自身反应性B细胞的CAR-T细胞策略可能用于自身免疫性疾病的靶向治疗。
研究设计与样本
- 本文为综述,讨论通过CAR-T细胞靶向自身反应性B细胞的演进策略。
主要发现
- 自身反应性B细胞在系统性红斑狼疮、类风湿关节炎和多发性硬化等自身免疫性疾病发病中起关键作用。
- 利妥昔单抗等B细胞清除单克隆抗体在自身免疫性疾病中疗效不佳,主要因自身反应性B细胞持续存在于淋巴器官和炎症组织中。
- 过去2年内,靶向CD19抗原的自体CAR-T细胞被引入自身免疫性疾病治疗。
- CD19 CAR-T细胞诱导循环B细胞快速持续清除,并使难治性系统性红斑狼疮和皮肌炎获得完全临床和血清学缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the tremendous progress in the clinical management of autoimmune diseases, many patients do not respond to the currently used treatments. Autoreactive B cells play a key role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. B-cell-depleting monoclonal antibodies, such as rituximab, have poor therapeutic efficacy in autoimmune diseases, mainly due to the persistence of autoreactive B cells in lymphatic organs and inflamed tissues. The adoptive transfer of T cells engineered to target tumour cells via chimeric antigen receptors (CARs) has emerged as an effective treatment modality in B-cell malignancies. In the last 2 years treatment with autologous CAR T cells directed against the CD19 antigen has been introduced in therapy of autoimmune disease. CD19 CAR T cells induced a rapid and sustained depletion of circulating B cells, as well as in a complete clinical and serological remission of refractory systemic lupus erythematosus and dermatomyositis. In this paper, we discuss the evolving strategies for targeting autoreactive B cells via CAR T cells, which might be used for targeted therapy in autoimmune diseases.
引用
- Schett G, Mackensen A, Mougiakakos D, et al. CAR T-cell therapy in autoimmune diseases. Lancet. 2023. PMID: 37748491. doi:10.1016/S0140-6736(23)01126-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。